Miaoshun Biotech Secures Over RMB 100 Million Series A Funding Led by Zhongke Haichuang, WinX Capital as Exclusive Financial Advisor

VCBeat has learned that recently,Miaoshun (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Miaoshun Bio") announced the completion of its Series A financing round, raising over RMB 100 million. The round was led by Zhongke Haichuang, with participation from Yida Capital, GL Ventures, Titan Scientific & Technology Group Co., Ltd. (688133.SH), and Tongyu Fund. Kaicheng Capital served as the exclusive financial advisor.This round of financing has garnered recognition and support from state-backed funds, renowned investment institutions, and publicly listed companies. The funds raised will be primarily used to accelerate the development of a series of primary cell products along with their associated reagents and consumables, as well as to further strengthen the company’s commercialization capabilities both domestically and internationally.

Miaoshun Biotechnology is a company specializing in the R&D and isolation services of domestically produced cells, committed to becoming a one-stop provider of upstream cells, supporting reagents, and services for the cell and gene therapy (CGT) sector. Through years of R&D and operations, the company has emerged as a leader in the primary cell industry, establishing a production and sales network covering China. It offers industry-leading service quality and response times, achieving annual revenues exceeding RMB 100 million while maintaining rapid growth. Leveraging its extensive technological expertise accumulated over the years, Miaoshun plans to expand into a broader range of cell types in the future. Building on its primary cell products, the company aims to position itself as a one-stop biomedical/CGT upstream supplier, offering a comprehensive portfolio that includes upstream consumables for various cell types and CRO services.

Zhang Jinbao, Founder and CEO of Miaoshun Bio, stated:We sincerely appreciate the attention and support from all institutions for Miaoshun Biotech. Since our establishment, we have been committed to positioning Miaoshun as a leading enterprise serving China’s biopharmaceutical companies. Following the completion of this financing round, we will consolidate our existing core businesses while accelerating the domestic and international commercialization of supporting reagents and consumables, as well as the implementation of new business ventures such as CRO services. Meanwhile, the Kaicheng Capital team demonstrated exceptional professionalism and execution throughout the financing process, playing an indispensable role in providing guidance and facilitating communication during material preparation, institutional liaison, and transaction structuring. We look forward to maintaining a strong collaborative relationship with Kaicheng Capital.

Yida Capital stated:Miaoshun Biology is a pioneer and leader in the field of primary cell services in China, and its cell isolation services are widely trusted by domestic customers. The company’s team is enterprising, continuously optimizing and improving its service system while persistently developing reagents related to cell isolation and culture, thereby building a one-stop service platform in the cell therapy sector. We are pleased to participate in this round of financing for Miaoshun Biology and look forward to the company achieving greater breakthroughs, thereby supporting the development of China’s biopharmaceutical and cell therapy industries.

A relevant official from Titan Technology stated:Miaoshun Biology is a niche market leader in China’s immune cell services industry. The company has mastered core technologies for cell models and launched multiple domestically leading cell model products with performance comparable to international brands. Miaoshun is strategically expanding its portfolio of reagents, consumables, and services within the cell therapy sector, demonstrating significant potential to become a top-tier enterprise in this niche. Titan Science’s current downstream customers are primarily focused on the biopharmaceutical industry. Expanding Miaoshun’s core product technologies into the scientific research market—continuously reaching university and research institute laboratories as well as corporate R&D centers—aligns with Titan’s strategic plans for cultivating new markets and brand building. Titan Science’s equity investment in Miaoshun Biology will create opportunities for both parties to further achieve industrial synergy through capital ties.

Tongyu Fund stated:Amidst the overarching industry trend of increasing localization in China’s upstream life sciences sector, numerous enterprises specializing in raw materials, consumables, or instruments have emerged. In this context, highly attractive targets are those that have already become industry leaders and possess rare product offerings, a robust commercialization network, and significant growth potential, such as Miaoshun Bio. We also look forward to Miaoshun’s future evolution into a comprehensive biomedical service platform with diversified capabilities.

Kaicheng Capital stated:We sincerely appreciate the Miaoshun Biotech team’s trust in Kaicheng Capital, as well as the strong support from all participating investment institutions. It is our honor to have facilitated the company’s completion of this financing round. The company’s founder, Mr. Zhang Jinbao, brings extensive entrepreneurial experience and has led Miaoshun Biotech to become a leading enterprise in China’s primary cell sector. We are confident that under Mr. Zhang’s leadership, Miaoshun Biotech will grow into a leading upstream platform enterprise in China’s biopharmaceutical industry.

Weifang Zhongke Haichuang Equity Investment Partnership (Limited Partnership) is one of the venture capital sub-funds established under the National Fund for Technology Transfer and Commercialization. The National Fund for Technology Transfer and Commercialization was jointly established by the Ministry of Science and Technology and the Ministry of Finance, aiming to support the commercialization of scientific and technological achievements—particularly those generated with fiscal funding—through the establishment of venture capital sub-funds. Under the guidance and management of the National Center for Science and Technology Risk Development, directly affiliated with the Ministry of Science and Technology, Weifang Zhongke Haichuang Equity Investment Partnership (Limited Partnership) is committed to providing equity investments in non-listed high-tech enterprises engaged in the commercialization of scientific and technological achievements. To date, it has invested in multiple domestically leading enterprises specializing in the transfer and commercialization of high-tech scientific and technological achievements.

Addor Capital was established through the mixed-ownership reform of Jiangsu High-Tech Investment Group, a well-established and renowned venture capital firm. It consistently ranks among the industry leaders in terms of industry research capabilities, assets under management, and investment specialization, making it one of the most influential venture capital institutions in China. Over the past three years, Addor Capital has consecutively won awards such as “Annual Chinese Venture Capital Institution,” “Best Chinese Venture Capital Institution,” “Most Competitive Venture Capital Institution,” “Excellent Venture Capital Institution Excellence Award,” and “Top 10 Best Venture Capital Firms” on prestigious lists published by Zero2IPO Group, CVSource, Securities Times, the China Venture Capital Association, and Forbes, solidifying its position in the first tier of domestic venture capital firms.

GL Ventures is one of China’s most active venture capital platforms, dedicated to identifying and creating value for innovative companies, with a particular focus on key sectors such as new technologies, new energy, new materials, and new consumption. Since its independent launch in 2020, we have been committed to supporting the long-term development of early-stage innovative enterprises through our systematic DVC (Deep Value Creation) services.

Shanghai Titan Scientific Co., Ltd. (Stock Code: 688133), established in October 2007, specializes in providing one-stop laboratory products and supporting services to researchers and quality control professionals. Committed to becoming a changemaker in the scientific services sector, the company aims to better serve national strategies, safeguard the security of national scientific research materials, and facilitate corporate innovation and upgrading.

The Company provides comprehensive, one-stop solutions to laboratories in the fields of biopharmaceuticals, new materials, new energy, chemical engineering, fine chemicals, food and daily chemicals, and analytical testing through independent R&D, brand operation, brand agency, and integrated packaging services. Its offerings cover all stages of the customer journey, including R&D preparation, R&D execution, post-R&D activities, and production quality control, delivering competitive products and services.

The company has developed eight major product lines centered on customer needs: high-end reagents, general-purpose reagents, analytical reagents, specialty chemicals, safety and security consumables, instruments and meters, laboratory construction, and scientific research software. Since its inception, the company has cumulatively served over 50,000 institutional clients and more than 1 million researchers.

Tongyu Fund is an emerging investment institution focused on healthcare, pharmaceuticals, and related sectors across their upstream and downstream industry chains. Guided by clinical needs and driven by the exploration of technological innovations in medical health, Tongyu Fund has assembled a professional team comprising top global scientists, seasoned venture capitalists, and experts with extensive corporate operational experience. By strategically positioning itself across the entire medical health ecosystem, the fund boasts deep industry penetration and broad market coverage, striving to become a leading professional investment institution in China’s medical health sector.

WinX Capital is a leading investment bank in China’s healthcare sector. Headquartered in Beijing and Shanghai, it serves over 3,000 active institutional investors and industrial groups. From 2020 to 2022, WinX Capital was consecutively recognized by Qimingpian & Xinsheng Chuangfu as “Top 2 Best Financial Advisors in Healthcare (2021–2022),” “Top 4 Best Financial Advisory Firms in Healthcare (2020),” “Top 10 Best Financial Advisors – Active List (2021),” “Top 6 Best Financial Advisors – Comprehensive List (Mid-2022),” and “Top 7 Best Financial Advisors – Active List (Mid-2022).” It was also ranked among the “Top 5 Most Promising New Investment Banks in China (WISE 2020/2021)” by 36Kr and named “Top 5 Healthcare Financial Advisor of the Year” at VCBeat’s 2022 Pengcheng Awards.